Human NTSR2 Stable Cell Line-CHO-K1

Neurotensin receptor 2 (NTSR2) is a G protein-coupled receptor that plays a crucial role in mediating the biological effects of neurotensin, a neuropeptide involved in multiple physiological processes. This receptor is encoded by the NTSR2 gene, located on human chromosome 2 (2q14.1). This gene contains multiple exons and is transcribed into a protein with seven transmembrane domains, characteristic of G protein-coupled receptors (GPCRs). Upon binding to NTSR2, neurotensin activates intracellular signaling pathways, including phospholipase C activation and calcium mobilization, thereby affecting neuronal excitability, pain regulation, and dopamine regulation. NTSR2 dysfunction is associated with neurological disorders such as schizophrenia, Parkinson's disease, and chronic pain syndromes. Studies have shown that NTSR2 is involved in cancer progression, particularly in breast and prostate cancer, promoting cell proliferation and metastasis through interactions with oncogenic pathways. The structure-function relationship and ligand-binding specificity of this receptor make it a potential therapeutic target for modulating neurotensin-mediated signaling cascades.

The Human NTSR2 Stable Cell Line – CHO – is a genetically engineered Chinese hamster ovary (CHO) cell line designed to stably express human neurotensin receptor 2 (NSR2). The CHO host system offers several advantages, including fidelity in post-translational modifications, robust growth in serum-free suspension culture, and scalability for high-throughput applications. This cell line has undergone rigorous functional validation, including radioligand binding assays (using [³H]-neurotensin), GTPγS binding assays (to confirm G protein coupling), and calcium ion flux assays (to demonstrate signal transduction). Applications of this cell line include screening for NTSR2 agonists/antagonists in drug discovery, studies of receptor internalization and transport kinetics, and research on the role of neurotensin in cancer biology.